Walradt Trent, Jirapinyo Pichamol
Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts and Harvard Medical School, Boston, MA 02115, USA.
Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts and Harvard Medical School, Boston, MA 02115, USA.
Trends Endocrinol Metab. 2025 Apr;36(4):373-385. doi: 10.1016/j.tem.2024.11.001. Epub 2024 Nov 29.
Obesity has become a global pandemic that is associated with a range of metabolic disorders. Traditional treatment options, such as lifestyle modification and anti-obesity medications, often exhibit limited efficacy and can lead to long-term weight gain, especially upon discontinuation of the medication. Although bariatric surgery is effective, its accessibility is constrained, and only a small percentage of eligible patients receive this intervention. Over the past two decades, endoscopic bariatric and metabolic therapies (EBMTs) have emerged as minimally invasive and effective alternatives for managing obesity and its related comorbidities. This article reviews primary gastric and small bowel EBMTs, their mechanisms of action, key supporting literature, and the metabolic outcomes associated with each device and procedure.
肥胖已成为一种全球性的流行病，与一系列代谢紊乱相关。传统的治疗方法，如生活方式改变和抗肥胖药物，往往疗效有限，并且可能导致长期体重增加，尤其是在停药后。尽管减肥手术有效，但其可及性受限，只有一小部分符合条件的患者接受这种干预。在过去二十年中，内镜减肥和代谢疗法（EBMTs）已成为治疗肥胖及其相关合并症的微创且有效的替代方法。本文综述了主要的胃和小肠EBMTs、它们的作用机制、关键支持文献以及与每种设备和手术相关的代谢结果。
